{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259332209", "close" : "1259344809", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
prnewswire

GenVec to Present at Merriman Curhan Ford's Investor Summit 2009

  • Press Release
  • Source: GenVec, Inc.
  • On 8:47 am EST, Tuesday November 3, 2009

GAITHERSBURG, Md., Nov. 3 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC - News) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the Merriman Curhan Ford's 6th Annual Investor Summit on Tuesday, November 10, 2009 at 9:20 am EST at Sofitel Hotel in New York, NY.

Related Quotes

SymbolPriceChange
GNVC1.00-0.02
Chart for GenVec, Inc.
{"s" : "gnvc,merr","k" : "c10,l10,p20,t10","o" : "","j" : ""}

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

A webcast of Dr. Fischer's presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data." The replay will be available 24 hours after the live presentation and will be accessible for 30 days.

More information about the conference can be found at: www.mcfco.com.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

About Merriman Curhan Ford

Merriman Curhan Ford (Nasdaq: MERR - News) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.

    Investor Contact:         Media Contact:
    GenVec, Inc.              Tiberend Strategic Advisors, Inc.
    Danielle M. DiPirro       Andrew Mielach
    (301) 944-1877            (212) 827-0020
    ddipirro@genvec.com       amielach@tiberendstrategicadvisors.com

Sponsored Links

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.